Partnering opportunities with AIMM Therapeutics
AIMM has a long history of partnering with the research community and commercial partners. These partnerships range from antibody specific deals for advancing candidates through clinical trials (i.e., Crucell/J&J and Medimmune/AZ), to academic research programs. AIMM intends to continue pursuing the broad utilization of its technology platforms and welcomes proposals from third parties that target diseases of high unmet medical need.
- Active collaborations for antibody discovery
- Platform licensing with tech transfer guidance
- Licensing a specific therapeutic from the AIMM pipeline
Academic collaborators are invited to submit proposals for working with AIMM.